<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/59ECC596-5CDA-4961-9695-94B905842BA0"><gtr:id>59ECC596-5CDA-4961-9695-94B905842BA0</gtr:id><gtr:name>Hemair Systems</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/28DC780F-3CEC-45AB-A937-2F1EC468705B"><gtr:id>28DC780F-3CEC-45AB-A937-2F1EC468705B</gtr:id><gtr:name>Eindhoven University of Technology</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AB307619-D4FA-427E-A042-09DBEBA84669"><gtr:id>AB307619-D4FA-427E-A042-09DBEBA84669</gtr:id><gtr:name>Swansea University</gtr:name><gtr:address><gtr:line1>Singleton Park</gtr:line1><gtr:postCode>SA2 8PP</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/33952E5D-60ED-4D33-8638-669D9CFF6674"><gtr:id>33952E5D-60ED-4D33-8638-669D9CFF6674</gtr:id><gtr:name>Swiss Federal Institute of Technology (ETH), Zurich</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/618C6FA2-F2EB-4646-BB45-7927F09D69C4"><gtr:id>618C6FA2-F2EB-4646-BB45-7927F09D69C4</gtr:id><gtr:name>Helmholtz Zentrum M?nchen</gtr:name><gtr:address><gtr:line1>German Center f. Environmental Research</gtr:line1><gtr:line2>Ingolst?dter Landstr. 1</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/FAD72F10-05DD-4B4D-89F4-0475C2A79E10"><gtr:id>FAD72F10-05DD-4B4D-89F4-0475C2A79E10</gtr:id><gtr:name>School of Pharmacy</gtr:name><gtr:department>Pharmaceutics</gtr:department><gtr:address><gtr:line1>29-39 Brunswick Square</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1N 1AX</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FAD72F10-05DD-4B4D-89F4-0475C2A79E10"><gtr:id>FAD72F10-05DD-4B4D-89F4-0475C2A79E10</gtr:id><gtr:name>School of Pharmacy</gtr:name><gtr:address><gtr:line1>29-39 Brunswick Square</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1N 1AX</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/59ECC596-5CDA-4961-9695-94B905842BA0"><gtr:id>59ECC596-5CDA-4961-9695-94B905842BA0</gtr:id><gtr:name>Hemair Systems</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/28DC780F-3CEC-45AB-A937-2F1EC468705B"><gtr:id>28DC780F-3CEC-45AB-A937-2F1EC468705B</gtr:id><gtr:name>Eindhoven University of Technology</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AB307619-D4FA-427E-A042-09DBEBA84669"><gtr:id>AB307619-D4FA-427E-A042-09DBEBA84669</gtr:id><gtr:name>Swansea University</gtr:name><gtr:address><gtr:line1>Singleton Park</gtr:line1><gtr:postCode>SA2 8PP</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/33952E5D-60ED-4D33-8638-669D9CFF6674"><gtr:id>33952E5D-60ED-4D33-8638-669D9CFF6674</gtr:id><gtr:name>Swiss Federal Institute of Technology (ETH), Zurich</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/618C6FA2-F2EB-4646-BB45-7927F09D69C4"><gtr:id>618C6FA2-F2EB-4646-BB45-7927F09D69C4</gtr:id><gtr:name>Helmholtz Zentrum M?nchen</gtr:name><gtr:address><gtr:line1>German Center f. Environmental Research</gtr:line1><gtr:line2>Ingolst?dter Landstr. 1</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/19CF3B06-7D27-49BD-89BB-6C1858DF976D"><gtr:id>19CF3B06-7D27-49BD-89BB-6C1858DF976D</gtr:id><gtr:name>Abertawe Bro Morgannwg NHS Trust</gtr:name><gtr:address><gtr:line1>Depatment of Emergency Medicine</gtr:line1><gtr:line2>Morriston Hospital</gtr:line2><gtr:line3>Morriston</gtr:line3><gtr:postCode>SA6 6NL</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/80AB401F-CF54-4A25-82AA-350655FD360E"><gtr:id>80AB401F-CF54-4A25-82AA-350655FD360E</gtr:id><gtr:name>Boots Centre for Innovation BCI</gtr:name><gtr:address><gtr:line1>Institute of Life Science</gtr:line1><gtr:line2>Swansea University</gtr:line2><gtr:line3>Singleton Park</gtr:line3><gtr:postCode>SA2 8PP</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/509FBD0D-BA30-4015-B269-33698EA4F05A"><gtr:id>509FBD0D-BA30-4015-B269-33698EA4F05A</gtr:id><gtr:firstName>Khuloud</gtr:firstName><gtr:otherNames>T</gtr:otherNames><gtr:surname>Al-Jamal</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2D97843F-E4A8-469D-A39A-88CA317DC3EB"><gtr:id>2D97843F-E4A8-469D-A39A-88CA317DC3EB</gtr:id><gtr:firstName>Kostas</gtr:firstName><gtr:surname>Kostarelos</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FG061998%2F1"><gtr:id>9048ED4C-E65D-4862-83C6-0D424585957E</gtr:id><gtr:title>Point of care nanotechnology for early blood clot detection and characterisation in disease screening, theranostic and self monitoring applications</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/G061998/1</gtr:grantReference><gtr:abstractText>Thromboembolic disease and associated blood coagulation abnormalities cause significant morbidity and mortality in Western society, with stroke being the third leading cause of death in the UK. The incidence of stroke increases markedly with age and is often higher in socially deprived areas. In stroke, the processes of endothelial and vascular damage, activation of the coagulation cascade and decreased fibrinolysis result in abnormal clots, often with excessively cross-linked fibrin networks. An unsatisfactory aspect of work in this area is that the microstructures of such clots are usually reported in only adjectival terms (e.g., dense or tight ) - usually on the basis of a visual inspection of fragments of dessicated clots in SEM micrographs. Early detection of clots is vital. Early clotting events may contribute to a pro-thrombotic state which exacerbates the disease state and thrombotic states can be followed rapidly by haemorrhagic states due to adverse changes in clot structure. The available therapeutic options informed by early detection and characterisation are greatly enhanced.New technology is essential to address shortcomings in this area. This project will exploit our recent advances in blood clot detection and ultra-sensitive nanomaterials development for device applications to overcome these shortcomings. Under a Royal Society Brian Mercer Award and an EPSRC Portfolio Partnership Award, in collaboration with the NHS, we have developed a new haemorheological technique for the early detection and characterisation of blood clots. This has led to the discovery that the incipient clot's fractal microstructure is a biomarker for the conditions of clot formation, including therapeutic intervention. The significance of this discovery stems from the incipient clot's role as the microstructural template for ensuing clot development. In parallel work we have demonstrated the controlled reproducible growth of vertical arrays of ZnO nanowires and have confirmed their electrical current generation capabilities. Our Grand Challenge proposal involves combining this nanotechnology with our haemorheological work to develop the first point of care (POC) device capable of the early detection and characterisation of abnormal clots. By a point of care device we refer to technology suitable for widespread use outside hospitals (i.e., within pharmacies and surgeries) and which will ultimately be developed for use by patients at home. This will exploit the piezoelectric properties of ZnO nanowire arrays as a transducer to detect shear wave propagation within coagulating blood. Our aim is to drastically improve the sensitivity of early clot detection for more accurate assessments of (i) coagulation abnormalities and (ii) therapeutic targeting of abnormal clots at the earliest stage of development. The project involves in vivo and in vitro disease model (Stroke) work at University of London, and work intended to enable our device to perform a therapeutic function. In this way we propose to lay the foundations for a POC system for Patient Self Assessment and Patient Self Management in anticoagulant applications, in addition to a new technological basis for thromboembolic disease screening. The project also includes anticoagulated Stroke patient volunteers at Morriston NHS Hospital.We have a highly multidisciplinary Team with internationally leading expertise in rheometry and haemorheology; nanotechnology, nanomaterials and nanofabrication; nanomedicine and drug delivery; and human-device interaction aspects of medical instrument design. We have two partners. The first is the NHS who will provide clinical facilities and governance of clinical research. Our second partner is Boots Centre for Innovation (BCI) whose involvement anticipates healthcare provision involving POC applications in next-generation pharmacies. BCI's role is to inform design relating to customer needs/experience, the POC market and environment.</gtr:abstractText><gtr:fund><gtr:end>2012-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2009-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>616741</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Helmholtz Zentrum M?nchen</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Institute for Biological and Medical Imaging</gtr:department><gtr:description>Track nanoparticles in vivo</gtr:description><gtr:id>27301D28-5C50-453F-9B76-312F9121211A</gtr:id><gtr:outcomeId>b97312cab97312de-1</gtr:outcomeId><gtr:piContribution>5 day visit to the Institute for Biological and Medical Imaging (IBMI), Helmholtz Centre, Munich to track nanoparticles in vivo using multi-spectral optoacoustic technology.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eindhoven University of Technology</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Functionalisation of carbon based nanomaterials with contrast agents for diagnosis using the MRI technique</gtr:description><gtr:id>2F2DF2B6-0CB8-41FC-AEAC-08334F9FDEFA</gtr:id><gtr:outcomeId>b9665dd2b9665df0-1</gtr:outcomeId><gtr:piContribution>Collaboration with Department of Biomedical Engineering in Eindhoven University of Technology for the functionalisation of carbon based nanomaterials with contrast agents for diagnosis using the MRI technique.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>ETH Zurich</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>Institute of Robotics and Intelligent Systems</gtr:department><gtr:description>Development of wireless drug delivery system with magnetic field actuation Description *</gtr:description><gtr:id>101CEE92-E4C7-468C-8949-A58092401EDB</gtr:id><gtr:outcomeId>b9666142b9666160-1</gtr:outcomeId><gtr:piContribution>A navigatable and wirelessly actuated by a magnetic field polymer matrix was engineered and developed for controlled and targeted drug delivery.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Swansea University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>The effect of carbon nanotubes on rheological properties</gtr:description><gtr:id>B3AEC0DD-B08B-4A1A-9A03-EA9279ED8EAD</gtr:id><gtr:outcomeId>b973945cb9739470-1</gtr:outcomeId><gtr:piContribution>2 day visit to Swansea University to perform haemorheological experimentation in human blood with Karl Hawkins. The effect of carbon nanotubes on rheological properties was examined.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hemair Systems</gtr:collaboratingOrganisation><gtr:country>India, Republic of</gtr:country><gtr:description>Development of new device.</gtr:description><gtr:id>3333D2F4-357B-4B25-B3A1-4FD8AE761946</gtr:id><gtr:outcomeId>b973dac0b973dade-1</gtr:outcomeId><gtr:piContribution>1 day visit to Swansea University for discussions with Biotech company, Hemair, and Rhodri Williams regarding the development of a new device.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Nanotubes inject stroke therapy into rats' brains</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>45D1C2C1-DADE-49A5-A26A-ED6F74DC6329</gtr:id><gtr:impact>http://www.rsc.org/chemistryworld/News/2011/June/21061102.asp.</gtr:impact><gtr:outcomeId>r-6553823981.9498960bc6a9b4</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.rsc.org/chemistryworld/News/2011/June/21061102.asp</gtr:url><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Nanomedicine Lab website</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4E8E4DAE-4BEB-4DE8-BC69-25FCB2FA4F83</gtr:id><gtr:impact>The Nanomedicine Lab describes the in its website the project and the acknowledges its contribution to advance the research conducted.</gtr:impact><gtr:outcomeId>r-8247275732.6879310b9b2500</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:url>http://www.nanomedicinelab.com/cooperation-and-support/collaborations/</gtr:url><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Nanonews Net on the PNAS article</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4DA91851-8796-4D82-BBD1-F4CF2338B877</gtr:id><gtr:impact>http://www.nanonewsnet.ru/news/2011/dlya-lecheniya-ishemicheskogo-insulta-vpervye-oprobovany-uglerodnye-nanotrubki-dostavlyayu.</gtr:impact><gtr:outcomeId>r-4251079423.5869120bcfd8b8</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.nanonewsnet.ru/news/2011/dlya-lecheniya-ishemicheskogo-insulta-vpervye-oprobovany-uglerodnye-nanotrubki-dostavlyayu</gtr:url><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk softly but carry a tiny stick: Stroke prevention and recovery with nanotube-delivered siRNA</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>50DD6A5C-C710-4581-972E-16CC6906003E</gtr:id><gtr:impact>http://medicalxpress.com/news/2011-07-softly-tiny-recovery-nanotube-delivered-sirna.html
.</gtr:impact><gtr:outcomeId>r-1249024189.30923940bc6ab4e</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://medicalxpress.com/news/2011-07-softly-tiny-recovery-nanotube-delivered-sirna.html</gtr:url><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>117753</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Engineering Responsive Nanomaterials for Pulsatile Neural Regeneration</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>E1AF9DFC-A15A-4EE6-A906-DC5AD716A666</gtr:id><gtr:outcomeId>5edd6cda5edd6cee</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The significant clinical (screening and monitoring) potential of the new haemorheological biomarkers exploited in the work under report led to the award of &amp;pound;1.5M in 2011 to establish a new Haemostasis Biomarker Research Unit at Morriston NHS Hospital. Within this new Unit the prototype/proof of concept point of care rheometrical devices developed during the work under report are being assessed and validated alongside conventional haemorheological and clot assay techniques, with 9 new staff appointments (Clinical Fellows, Clinical Haemorheologists and Research Nurses) taking the technology from the laboratory to use at the point of care in (i) operating theatres; (ii) treatment rooms and (iii) on patient wards, in collaboration with partner NHS Consultants in seven carefully chosen Care Pathways (including stroke, sepsis, diabetes, cancer and trauma). In addition, these point of care assessment/validation studies include the effects of fluid dilution, temperature change and aniplatelt therapy including aspirin).</gtr:description><gtr:id>DFE23983-F9BB-4B73-A609-42CE2A68BA4F</gtr:id><gtr:impactTypes><gtr:impactType>Cultural</gtr:impactType></gtr:impactTypes><gtr:outcomeId>m-3676794193.384046de253ce6</gtr:outcomeId><gtr:sector>Cultural,Policy &amp; Public Services</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>Electro-responsive polymer matrices were developed as the therapeutic component of the first point of care (POC) device capable of the early detection and characterisation of abnormal clots. Stimuli-responsive hydrogel hybrids were engineered to allow the device to perform a therapeutic function, and to deliver drug in a pulsatile manner, remotely controlled by the ON/OFF application of an electric voltage generated by the device when the detection of a clot occurs. The drug delivery system is composed of multi-walled carbon nanotubes (MWNTs) incorporated in an electro-responsive hydrogel matrix such as poly (methyl methacrylate) (PMAA). The use of MWNTs considerably improved the sensitivity and response of the hydrogel hybrids to the applied electric field compared to the hydrogels without MWNTs. The pulsatile release of a model drug in the blood upon the application of the electric field was also demonstrated in vivo when the hybrid gels were subcutaneously implanted in mice. The MWNT hybrid gels demonstrated higher drug release and sharper responses to the electric field, significantly outperforming the blank gel during the same time period and under the same conditions of stimulation. An optimisation of the system was explored by using graphene sheets as nanofillers of the PMAA hydrogel matrix. These novel graphene gel hybrids demonstrated higher drug release capabilities than the MWNT hybrid gels.



A systemic model of thrombosis was selected to enable comparison with clinical blood samples and lay the groundwork for point-of-care device testing. Intravenous injection of thrombin was used to induce a widespread prothrombotic state without causing animal death and reduced occurrence of stroke compared to other methods to induce systemic thrombosis. The thrombin-induced systemic model was characterised and compared to healthy animals using a wide range of techniques. Traditional methods were used in conjunction with our haemorheological technique for the early detection and characterisation of blood clots. The prothrombotic state of the disease model was confirmed by: platelet aggregate formation (full blood profile); a 4-fold increase in the number of activated platelets (flow cytometry); a ten-fold increase in thrombin-antithrombin levels (ELISA); observation of more compact fibrin networks in the clot structure (scanning electron microscopy) and thromboembolisms (histological analysis). Together these data confirm that this in vivo model is prothrombotic. Employing our haemorheological technique, clotting time was reduced by half and the mature clot was 2.5 times more rigid in structure in blood from the disease model. This is the first time that haemorheological measurements have been made in mouse. It is possible to measure blood samples from both healthy and diseased mice. This in vivo model of thrombosis is suitable for validation of the point-of-care device.</gtr:description><gtr:exploitationPathways>Work under the grant involving samples of blood was conducted principally in collaboration with our partner, ABMU NHS Trust at the NHS Morriston Hospital EPSRC-NHS Clinical Haemorheology Labaoratory (opened in 2005). The routes for exploiting such sensitive and stimuli-responsive delivery systems for industrial applications rely on the capacity of these gels to be easily attached on, and form a part of the device developed for early clot detection. The pulsatile delivery of anticoagulant agents such as heparin or warfarin could be generated subsequently to the early detection of a clot combining diagnosis and therapy in a single device.</gtr:exploitationPathways><gtr:id>549DD34F-7761-4690-ABAD-0C6DEA65CDCF</gtr:id><gtr:outcomeId>r-3898919870.98280337781d384</gtr:outcomeId><gtr:sectors><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors><gtr:url>http://www.nanomedicinelab.com/cooperation-and-support/collaborations/</gtr:url></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Intravenous injection of 5U/ml thrombin into mouse tail vein to induce a procoagulant state.</gtr:description><gtr:id>0ECA6023-7C4B-4954-BA22-E8022FE470CB</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>r-3987799830.7233677c6b5ed3a</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Systemic thrombosis mouse model</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Subcutaneous implantation of hybrid gel, stimulation of drug release by electrical stimulation and subsequent blood sampling and analysis.</gtr:description><gtr:id>5E0595EF-8F73-41C5-86AB-2DDD8E4629BB</gtr:id><gtr:impact>Subsequent studies from other laboratories have repeated the experimental method described with success</gtr:impact><gtr:outcomeId>r-6783151502.519056c6b5ec4a</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Subcutaneous gel release model</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>PMAA-MWNT hydrogel hybrids were fabricated by in-situ radical polymerisation; the concentration of multi walled carbon nanotubes (MWNTs) and of the cross-linker was optimised in order to obtain hydrogels with enhanced responses to the electric field. The incorporation of MWNTs within the polymeric network, confirmed by SEM, improved the physical properties of the hybrids by decreasing significantly the bulk resistivity of the polymeric matrix and improving the thermal properties of the polymeric matrix.</gtr:description><gtr:id>C532FD78-0491-43EF-B2CB-53C0C751823B</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>r-4572985958.8416166fd24c6a</gtr:outcomeId><gtr:title>MWNT/Graphene Hydrogel hybrids</gtr:title><gtr:type>New Material/Compound</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput><gtr:softwareAndTechnicalProductOutput><gtr:description>An injectable electro-responsive hybrid polymeric implant for the pulsatile and targeted delivery in the brain of Retinoic acid (RA), a growth factor that plays a crucial role in neuron patterning, differentiation and survival in the brain was developed.</gtr:description><gtr:id>2C72CB39-200C-4B19-A95C-2A749E250CC3</gtr:id><gtr:impact>Prototype for future studies</gtr:impact><gtr:outcomeId>r-9107660920.4594616fd4366a</gtr:outcomeId><gtr:title>Injectable hydrogel hybrids for controlled drug delivery</gtr:title><gtr:type>Systems, Materials &amp; Instrumental Engineering</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput><gtr:softwareAndTechnicalProductOutput><gtr:description>A novel MEMS based drug delivery device has been developed, consisting of an array of metallic contacts on silicon and Pyrex glass wafers. The meander structured device creates a uniform electric field which stimulates drug release. An electro-active hydrogel based polymer matrix has also been developed, which responds to an electrical stimulus and shrinks or de-swells on application of an electric field from the fabricated device. Different drug candidates can be encapsulated within the polymer matrix. The de-swelling of the polymer enables the encapsulated drug to be released from the matrix.</gtr:description><gtr:id>500EE410-35B5-4CC2-9612-246B47717DCA</gtr:id><gtr:impact>Prototype for further industrial development</gtr:impact><gtr:outcomeId>r-3807553736.313761771e59572</gtr:outcomeId><gtr:title>Novel MEMS druge delivery device</gtr:title><gtr:type>Physical Model/Kit</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput><gtr:softwareAndTechnicalProductOutput><gtr:description>Haemorheological measurements have not been performed previously. The technique used for human blood was adapted for use small volumes of mouse blood sample (approx 600ul). This has made it possible to compare haemorheological data from mouse to clinical samples. Dr Methven did the adaptation of human technique and development of protocol for heamorheological technique in mouse blood experiments. Dr Karl Hawkins did the rheological training, development of protocol for heamorheological technique in mouse blood experiments.</gtr:description><gtr:id>35B01310-ACB8-4669-B586-180E8367C505</gtr:id><gtr:impact>Preclinical evidence to educate clinical trial design</gtr:impact><gtr:outcomeId>r-1361762640.40336256fd43e3a</gtr:outcomeId><gtr:title>Haemorheological technique in mouse blood</gtr:title><gtr:type>New/Improved Technique/Technology</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput><gtr:softwareAndTechnicalProductOutput><gtr:description>High-specification rheometer was transported to and used at School of Pharmacy for mouse blood samples to mimic the clinical data obtained at Swansea University and CHL Morriston Hospital.</gtr:description><gtr:id>37E82D0D-EF14-4EB4-A8DB-32BA87DFAE94</gtr:id><gtr:impact>Prototype for clinical trial design</gtr:impact><gtr:outcomeId>r-8786322845.878386fd231c6</gtr:outcomeId><gtr:title>Mimicking clinical experiments with mouse blood</gtr:title><gtr:type>New/Improved Technique/Technology</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput><gtr:softwareAndTechnicalProductOutput><gtr:description>A navigatable and wirelessly actuated by a magnetic field polymer matrix was engineered and developed for controlled and targeted drug delivery.</gtr:description><gtr:id>1D5FB011-EA72-421D-8343-848A72864CB9</gtr:id><gtr:impact>Further studies on magnetic actuation of micro- and nano-particles</gtr:impact><gtr:outcomeId>r-452339053.57526536fd4837c</gtr:outcomeId><gtr:title>Development of wireless drug delivery system with magnetic field actuation</gtr:title><gtr:type>New/Improved Technique/Technology</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B270167B-014F-4AA2-8CED-0B1F06448FD1</gtr:id><gtr:title>Electro-resonsive PMAA-MWNT hydrogel hybrids for in vivo remote-controlled drug delivery</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c978b5cc6716e964963daec51b2247e"><gtr:id>9c978b5cc6716e964963daec51b2247e</gtr:id><gtr:otherNames>Kostas Kostarelos (Co-author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>m_439182217913ec9a88</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22D74F0A-DD78-4C6E-BBF9-693C9E319EC0</gtr:id><gtr:title>Chemically functionalized carbon nanotubes as drug delivery system for the brain</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c978b5cc6716e964963daec51b2247e"><gtr:id>9c978b5cc6716e964963daec51b2247e</gtr:id><gtr:otherNames>Kostas Kostarelos (Co-author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>r_3907828977caca2e04</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B704D03-31E4-4593-90AD-4505E6493C14</gtr:id><gtr:title>Functional motor recovery from brain ischemic insult by carbon nanotube-mediated siRNA silencing.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb5d65786130fa33d5c7db8a4e025b56"><gtr:id>eb5d65786130fa33d5c7db8a4e025b56</gtr:id><gtr:otherNames>Al-Jamal KT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>doi_53d03a03a4bda40e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C11E26F-CE7A-4933-9CFB-B52F9CFE47C1</gtr:id><gtr:title>An electric-field responsive microsystem for controllable miniaturised drug delivery applications</gtr:title><gtr:parentPublicationTitle>Sensors and Actuators B: Chemical</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7c92a675b6502a97a707b04cca69bc1"><gtr:id>d7c92a675b6502a97a707b04cca69bc1</gtr:id><gtr:otherNames>Liu Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>doi_53d00a00aaef00fb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8629A04-1ABE-4424-8F48-A8E4A5C96839</gtr:id><gtr:title>An Electric-Field Responsive Microsystem for Controllable Miniaturised Drug Delivery Applications</gtr:title><gtr:parentPublicationTitle>Procedia Engineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7c92a675b6502a97a707b04cca69bc1"><gtr:id>d7c92a675b6502a97a707b04cca69bc1</gtr:id><gtr:otherNames>Liu Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>doi_53d006006ab75e9f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81DC0E3F-E51D-4087-877D-4FE17F6D9D94</gtr:id><gtr:title>The relationship between the diameter of chemically-functionalized multi-walled carbon nanotubes and their organ biodistribution profiles in vivo.</gtr:title><gtr:parentPublicationTitle>Biomaterials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c77de6f25ddbd82e1ab5917a13a35f63"><gtr:id>c77de6f25ddbd82e1ab5917a13a35f63</gtr:id><gtr:otherNames>Wang JT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0142-9612</gtr:issn><gtr:outcomeId>585d6244b38362.15237784</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18283E01-6517-4029-A479-BDF0389CE2A0</gtr:id><gtr:title>Gel point and fractal dimension of incipient blood clots are significant new biomarkers for stroke in in-vivo and in-vitro disease animal model studies.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76da9e21b9fcf2f6219adcef0b170968"><gtr:id>76da9e21b9fcf2f6219adcef0b170968</gtr:id><gtr:otherNames>Laura Methven  (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>m_642226482213680b4c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CFF5C48-64E5-449D-9D6F-3BB192ED8261</gtr:id><gtr:title>Electro-responsive pristine multi-walled carbon nanotube/methacrylic acid based hydrogel hybrids for controlled drug delivery in vivo.</gtr:title><gtr:parentPublicationTitle>Advanced Healthcare Materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81ffdd9926ad93104efc3efd66444cb9"><gtr:id>81ffdd9926ad93104efc3efd66444cb9</gtr:id><gtr:otherNames>Ania  Servant  (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>m_2923463893136789ba</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2A42251-52A3-4095-B8EC-E2F37EAF1EFD</gtr:id><gtr:title>Graphene hydrogel hybrids: biomaterials with higher capabilities?</gtr:title><gtr:parentPublicationTitle>ACS Nano</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d2bc241ac02fdf536c93c96eb4be656"><gtr:id>3d2bc241ac02fdf536c93c96eb4be656</gtr:id><gtr:otherNames>A,  Servant  (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>m_487655865413677eca</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F833861A-48E1-4123-9F45-65D3CBAABA28</gtr:id><gtr:title>Can pro-coagulant properties of multi-walled carbon nanotubes be prevented?</gtr:title><gtr:parentPublicationTitle>Advanced Healthcare Materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76da9e21b9fcf2f6219adcef0b170968"><gtr:id>76da9e21b9fcf2f6219adcef0b170968</gtr:id><gtr:otherNames>Laura Methven  (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>m_74975461631367888e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82064685-7F86-4B35-A929-73195775A563</gtr:id><gtr:title>Engineering and Chemistry at the service of nanobiotechnology</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c62e6c24cfcc2e01111690d7fa38c543"><gtr:id>c62e6c24cfcc2e01111690d7fa38c543</gtr:id><gtr:otherNames>A. Servant  (Speaker)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>m_432167115413d67690</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CECB3983-4044-4B4F-8765-56B565619943</gtr:id><gtr:title>Preparation of graphene hydrogel hybrids by the Ball milling method</gtr:title><gtr:parentPublicationTitle>J Mat Chem</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1360c8a76fa156888ccfbd77b26e7d45"><gtr:id>1360c8a76fa156888ccfbd77b26e7d45</gtr:id><gtr:otherNames>E. Vasquez Fernandez-Pacheco (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>m_8206132836136acf8a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C228027-5D55-435E-BB4F-6D0422950457</gtr:id><gtr:title>Degree of chemical functionalization of carbon nanotubes determines tissue distribution and excretion profile.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb5d65786130fa33d5c7db8a4e025b56"><gtr:id>eb5d65786130fa33d5c7db8a4e025b56</gtr:id><gtr:otherNames>Al-Jamal KT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>doi_53cfc1fc17ec4272</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70EB54FB-BDD6-4CBA-8093-F70EFD128D1A</gtr:id><gtr:title>Modified MWNT show reduced hemolytic effect and do not induce anemia in vivo.</gtr:title><gtr:parentPublicationTitle>Small</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76da9e21b9fcf2f6219adcef0b170968"><gtr:id>76da9e21b9fcf2f6219adcef0b170968</gtr:id><gtr:otherNames>Laura Methven  (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>m_41464179431376e176</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>311CF33D-122E-41D9-87AF-E9FA5F3DB5DF</gtr:id><gtr:title>Engineering novel electro-responsive MWNT-PMAA hybrid hydrogels for pulsatile drug release</gtr:title><gtr:parentPublicationTitle>Biomaterials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3974d7eba5c3652fffd60f2c391b148b"><gtr:id>3974d7eba5c3652fffd60f2c391b148b</gtr:id><gtr:otherNames>A, Servant  (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>m_2007450737136800ca</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34F9A035-5069-4BF5-A9E8-FCFE47C1E7F6</gtr:id><gtr:title>Doubly chemically-functionalised thin multi-walled carbon nanotubes enhance tissue affinity in vivo</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c978b5cc6716e964963daec51b2247e"><gtr:id>9c978b5cc6716e964963daec51b2247e</gtr:id><gtr:otherNames>Kostas Kostarelos (Co-author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>r_3435193041cad45f46</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/G061998/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>6723A70B-A523-40AB-9740-B6AD2A0677B7</gtr:id><gtr:percentage>70</gtr:percentage><gtr:text>Medical &amp; health interface</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>99E0B904-CAB5-4511-AFB3-AA6D2B171F97</gtr:id><gtr:percentage>30</gtr:percentage><gtr:text>Process engineering</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>16595C3C-600D-4AD2-B394-16E06F96495F</gtr:id><gtr:percentage>70</gtr:percentage><gtr:text>Med.Instrument.Device&amp; Equip.</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>04DC091E-A791-4572-A9B7-E327BB0A3EB8</gtr:id><gtr:percentage>30</gtr:percentage><gtr:text>Particle Technology</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>